Osmol Therapeutics的封面图片
Osmol Therapeutics

Osmol Therapeutics

生物技术研究

New Haven,Connecticut 452 位关注者

Addressing the urgent need of patients faced with the challenges of CIPN and CICI through the advancement of OSM-0205

关于我们

Osmol Therapeutics is developing OSM-0205, our lead investigational candidate, to address the urgent need of patients faced with the challenges of chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI) - challenging and debilitating conditions impacting cancer patients worldwide. Nearly 50% of patients receiving taxane-based therapy must choose between risking sub-optimal cancer treatment outcomes associated with reducing chemotherapy dosage or the painful and debilitating impact of CIPN and CICI – conditions for which there are no effective treatments. Our groundbreaking approach aims to prevent CIPN and CICI before they impact patients – paving the way for optimal chemotherapy dosing and enhanced outcomes. OSM-0205, delivered intravenously just before chemotherapy, targets the essential interaction that initiates the calcium surge to prevent the cascade of neuronal damage leading to CIPN and CICI. Osmol Therapeutics is a privately held clinical stage biopharma company advancing a first-in-class treatment to prevent CIPN, based on the groundbreaking research of Dr. Barbara Ehrlich of Yale University, founder and chief scientific officer. For more information, please visit www.osmoltherapeutics.com. *COMMUNITY GUIDELINES* We value open discussions and encourage sharing insightful content about biotechnology, research advancements, and industry news. We encourage a respectful and collaborative environment where diverse perspectives are appreciated, and professional conduct is upheld at all times. Osmol reserves the right to hide, delete, or block messages and users we deem inappropriate on our LinkedIn page.

网站
https://osmoltherapeutics.com/
所属行业
生物技术研究
规模
2-10 人
总部
New Haven,Connecticut
类型
私人持股
创立
2016
领域
chemotherapy-induced peripheral neuropathy、CIPN、chemotherapy-induced cognitive impairment、CICI、OSM-0205、breast cancer、intracellular calcium、taxanes、taxane-based therapy、cancer treatment、chemotherapy、central nervous system、chemo brain、calcium surge和neuronal damage

地点

Osmol Therapeutics员工

动态

  • Despite decades of progress in oncology, the rate of chronic painful chemotherapy-induced peripheral neuropathy (CIPN) hasn’t budged.   A new global meta-analysis published in American Society of Regional Anesthesia and Pain Medicine (D’Souza et al., 2025) found that over 40% of patients with CIPN develop chronic pain, a number that’s remained stubbornly high for more than 20 years.   We’re grateful that the researchers are shining a light on this challenge, and we remain motivated to prevent CIPN and chemotherapy-induced cognitive impairment (CICI) before they start as we advance OSM-0205 into the clinic.

  • Congrats to Teresa Bitetti, a valued member of Osmol's Board, on her recent appointment to the Board of Directors at Aura Biosciences.   Teresa has been instrumental in shaping Osmol's strategic direction and commitment to addressing cancer patients' unmet needs, bringing sharp strategy and global impact—Aura is lucky to have her.

  • Find us at #VentureConnect2025 this week! Join our CEO, Bob Linke, as he presents during the Biopharma Track tomorrow, March 26, from 10:00 - 11:15 AM ET. Bob will share insights into our lead candidate, OSM-0205, and its potential to address chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI). Looking forward to connecting with fellow industry leaders at this important event. Learn more: https://bit.ly/423F5Bm

    • Join Osmol Bio at Venture-Connect 2025 | BioPharma Track Speaker: Bob Linke, CEO | March 26, 2025 at 10am ET
  • Currently, no alternative treatments have been approved for CIPN or CICI. Our lead candidate, OSM-0205, with a single IV dose 30 minutes before a taxane-based chemotherapy infusion, may prevent chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI) before they start. We're headed to the clinic soon to advance our Phase 1 clinical study. Replay is now available for #BiotechShowcase 2025, as presented by our CEO, Bob Linke: https://bit.ly/3FpqwjX

    • 该图片无替代文字
  • According to this article in Inside Precision Medicine, patients who experience painful CIPN symptoms often face significant limitations in their daily lives, a worse quality of life, and financial struggles. In addition, treatment outcomes and survival rates can be impacted when chemotherapy is reduced or discontinued entirely as a result of severe cases.   At Osmol, we believe patients shouldn’t have to choose between effective cancer treatment and their long-term quality of life. That’s why we’re working to prevent CIPN before it starts, allowing patients to focus on recovery—not lasting side effects.   Read the full article here: https://bit.ly/3Dt1YpB

    • Sunday, January 29, 2025: Four in Ten Chemotherapy-Treated Patients Have Chronic Peripheral Neuropathy via Inside Precision Medicine
  • DYKT Black breast cancer survivors may be disproportionately affected by chemotherapy-induced peripheral neuropathy (CIPN)? Learn about the research via Oncology Nursing News, which sheds light on how racial disparities in cancer care can leave lasting impacts on survivors. At Osmol, our work focuses on prevention, aiming to stop CIPN before it starts so patients can focus on recovery, not side effects. Read the full article: https://bit.ly/4htGtDO

    • 该图片无替代文字
  • Cancer treatment saves lives, but for many survivors, the journey doesn’t end when treatment stops. According to American Association for Cancer Research, 18 million cancer survivors in the U.S. are living with, through, and beyond their disease. For many, chemotherapy-induced peripheral neuropathy (CIPN) remains a debilitating, life-long side effect—impacting mobility, daily activities, and overall well-being. At Osmol, we are committed to preventing the overlooked challenges of cancer treatment. Our groundbreaking approach targets CIPN and chemotherapy-induced cognitive impairment (CICI), commonly associated with taxane-based chemotherapies, so patients don’t have to choose between treatment success and quality of life. This National Cancer Prevention Month, we also recognize the strength of survivors. By addressing the lasting effects of chemotherapy, we can improve outcomes and ensure that more patients thrive beyond their diagnosis. Learn how OSM-0205 is striving to address this critical challenge in cancer care: https://bit.ly/3WVNXaj

    • 该图片无替代文字
  • ✋ Who's headed to #NEXUS2025 in San Francisco for the week? 🗣️ Don't miss Bob Linke, CEO, as he discusses how OSM-0205's first-in-class mechanism is paving the way for improved patient outcomes by addressing chemotherapy-induced side effects like chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI). We're proud to contribute to these critical conversations to enhance patients' lives. Don't miss tomorrow's presentation during the Biopharma Track. https://bit.ly/426V6bi Blinkpad #JPMHealthcareWeek

    • 该图片无替代文字
  • We’re headed to #NEXUS2025 – a gathering of innovators, investors, and thought leaders shaping the future of healthcare. Our CEO, Bob Linke, will present during the Biopharma Track on Tuesday, January 14, in South San Fran. Bob will spotlight OSM-0205, our lead candidate, and its potential to transform cancer care by addressing chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI). Learn more and register here: https://bit.ly/426V6bi #JPMHealthcareWeek MT Blinkpad

    • 该图片无替代文字

相似主页

查看职位

融资